Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation

Overview

This pilot study aims to assess the impact of anxiety on the cardiac substrate remodeling in female patients with paroxysmal and persistent atrial fibrillation (AF).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: July 2020

Detailed Description

Hypothesis: High level of anxiety promotes remodeling of cardiac substrate via persistent inflammation, resulting in an increase in the prevalence of left atrial scar and non-pulmonary vein (non-PV) triggers in women with AF. Rationale: Anxiety is generally defined as a psycho-biological emotional state or reaction that consists of unpleasant feelings of tension, apprehension, nervousness, and worry, and activation of the autonomic nervous system. This disorder is typically more common in women than men. There is considerable evidence to suggest close interactions between anxiety and inflammation and inflammation and AF. Earlier studies have documented strong association between anxiety and inflammation as shown by high levels of inflammatory biomarkers such as C-reactive protein (CRP), total white blood cell (TWBC) count, fibrinogen and interleukin-6 in patients with anxiety. Chronic inflammation results in structural remodeling of the atrial architecture such as fibrotic changes that supports genesis and perpetuation of AF. In cardiac fibrosis, myocytes coupled with fibroblasts can undergo early depolarization resulting in increased ectopic beats and repetitive firing leading to the origin of non-pulmonary vein (non-PV) drivers. Left atrial scar is another known consequence of cardiac fibrosis. Therefore, it is prudent to hypothesize that high level of anxiety for prolonged period results in structural remodeling of cardiac substrates evidenced by increased prevalence of left atrial scar and non-PV triggers in female patients with paroxysmal and persistent AF. Scar and non-PV triggers are known independent predictors of arrhythmia recurrence in AF patients undergoing catheter ablation. Recurrences of AF, despite complete PV disconnection, strongly suggest an important possible role of these foci in serving as a source for the persistence of this arrhythmia. Altered conduction and barriers resulting from the atrial scar form the critical circuits for intra-atrial re-entry that promotes AF persistence. Recent progress in technology and knowledge have provided better understanding and allowed the electrophysiologists to improve on the ablation procedure in order to make it more safe and effective. However, there are still scores of unanswered questions in this relatively young research domain, one of which is if anxiety impacts cardiac substrate remodeling that potentially influences ablation-outcome. Also, of note, anxiety affects how patients perceive their illness, particularly for women, and influence healthcare utilization and economic burden. Therefore, if the role of anxiety would be ascertained, timely intervention of the same would lead to improvement in the success rate of the ablation therapy in females that highly dominate this subset of AF population. Study Design: This pilot study will prospectively enroll 152 consenting female patients undergoing catheter ablation for AF. Eligible patients will be enrolled after signing informed consent, approved by Institutional Review Board of the participating institution.

Interventions

  • Procedure: Catheter ablation
    • Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care

Arms, Groups and Cohorts

  • Active Comparator: Group 1: with baseline anxiety+catheter ablation
    • Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
  • Active Comparator: Group 2: Without baseline anxiety + catheter ablation
    • Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40

Clinical Trial Outcome Measures

Primary Measures

  • Correlation between baseline anxiety score and prevalence of left atrial scar and non-pulmonary vein triggers
    • Time Frame: intraoperative

Secondary Measures

  • Correlation of baseline anxiety score with scar severity
    • Time Frame: intraoperative
  • Correlation of baseline TWBC and CRP level with the anxiety score
    • Time Frame: baseline
  • Change in CAQ score
    • Time Frame: 12 months
  • Recurrence status
    • Time Frame: 1 year
    • Recurrence of AF/ AFlutter/ atrial tachycardia off or on anti-arrhythmic drugs
  • Change in HAD score
    • Time Frame: 12 months
  • Change in State-anxiety
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

1. Age: ≥ 18 years 2. Sex: female 3. Undergoing catheter ablation for paroxysmal or persistent AF 4. Able and willing to provide written informed consent Exclusion Criteria:

1. Receiving behavioral therapy or medications for the anxiety disorder 2. On hormonal supplement 3. On long-term steroid or anti-inflammatory drugs

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Texas Cardiac Arrhythmia Research Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrea Natale, Executive Medical Director – Texas Cardiac Arrhythmia Research Foundation
  • Overall Official(s)
    • Mitra Mohanty, MD MS FHRS, Principal Investigator, Texas Cardiac Arrhythmia Research Foundation
  • Overall Contact(s)
    • Mitra Mohanty, MD MS FHRS, 512-544-8198, mitra1989@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.